Cancer

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all…

1 year ago

Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy

Vironexis’s off-the-shelf, single-dose gene therapies aim to deliver cancer treatments that are safer, more effective and long-lasting, and more easily…

1 year ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well…

1 year ago

Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)

Biosplice expands its clinical candidate, cirtuvivint, as standalone treatment and combination therapy in patients with AML and MDS, representing next…

1 year ago

Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures

PITTSBURGH, Sept. 12, 2024 (GLOBE NEWSWIRE) -- MetasTx LLC, a biopharmaceutical company dedicated to developing innovative therapies for cancer metastasis,…

1 year ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a…

1 year ago

RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet’s Digital Health Division

Former Chief Business Leader of Philips’ multi-billion-dollar Precision Diagnosis division and member of Philips’ Executive CommitteeEnd-to-end responsibility for Philip’s CT,…

1 year ago

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/…

1 year ago

Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI

SINGAPORE, Sept. 12, 2024 /PRNewswire/ -- Qritive, a leading digital pathology and AI company headquartered in Singapore, is proud to…

1 year ago